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Abstract 
We have investigated the regulation by divalent cations Mg 2+, Ca 2+ and Mn 2+ of the functional activity of the human integrin VLA-1 expressed 
on neuroblastoma NB100 cells. VLA-l-mediated adhesion of NB100 ceils to ligand collagen type I was supported by either mM concentrations of 
extracellular Mg 2+ or/tM levels of Mn 2÷. In contrast, Ca 2+ alone did not induce activation of VLA-1 but exerted a potent inhibitory effect on the 
Mg2+-supported cell adhesion. We have also demonstrated that VLA-1 can be directly activated by the stimulatory monoclonal antibody TS2/16 
specific for the integrin fll subunit, resulting in effective adhesion of NB100 cells to type I collagen. This study has been possible by using a novel 
blocking VLA-ctl specific monoclonal antibody, 5E8D9. 
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1. Introduction 
Integrins are a family of heterodimeric ot/fl cell surface 
adhesion receptors that mediate interactions ofcells with 
components of the extracellular matrix (ECM) or with 
other cells (see [14] for recent reviews). All ~ and fl 
subunits of integrins hare a number of common struc- 
tural features. The integrin fl subunits are transmem- 
brane glycoproteins with a large extracellular domain 
containing a three-fold repeat of a cysteine rich segment 
and a 100-200 amino acid highly conserved region. The 
integrin 0~ subunits are also transmembrane glycopro- 
reins with a long extracellular region which contains in 
the N-terminal part seven homologous domains of ap- 
proximately 60 residues. Three or four of the seven ho- 
mologous domains are putative divalent cation binding 
sites which show sequences with homology to the Ca 2÷ 
binding proteins calmodulin, parvalbumin and troponin 
C. Consistent with this is the absolute requirement for 
divalent cations of integrins to mediate ffective interac- 
tion with ligands. 
One group within the integrins is the VLA subfamily 
containing at least nine members, each with a distinct 
subunit non-covalently associated with the common fll 
subunit [3,5,6]. Most VLA integrins eem to function 
essentially as cellular receptors for ECM proteins uch 
as collagen, laminin and fibronectin. However, VLA-4 
besides acting as a cellular eceptor for fibronectin also 
*Corresponding author. Fax: (34) (1) 394 16 91. 
Abbreviations: mAb, monoclonal antibody; ECM, extracellular cell 
matrix; COLL, collagen; LM, laminin; FN, fibronectin; IL-2, inter- 
leukin 2. 
mediates the interaction with a cellular ligand, VCAM-1, 
expressed on cytokine-activated endothelial cells [7] and 
has been implicated inhomotypic cell interactions a well 
[8]. Recently a role for VLA-2 and VLA-3 in cell-cell 
interactions has also been suggested [9-10]. 
The divalent cation requirements for specificity and 
affinity of ligand binding have been recently described 
for integrins VLA-2, VLA-3, VLA-4 and VLA-6 [11-17]. 
An emerging eneral feature in the mechanism by which 
different divalent cations regulate functional activity of 
these VLA integrins i  that both Mg 2+ at concentrations 
in the mM range and Mn 2÷ in the gM range induce an 
active state resulting in effective binding to ligands. Con- 
versely, Ca 2÷ generally exerts inhibitory effects on the 
function ofVLA integrins. These regulatory mechanisms 
of integrin activation are not restricted to the VLA (ill) 
subfamily since the interactions ofthe leukocyte (/32) and 
f13 integrins eem to be regulated by divalent cations in 
a similar manner [18-21]. 
Functional activation of integrins can also be experi- 
mentally induced from outside the cells with stimulating 
mAbs specific for either the ~ or the fl subunit which 
impose an integrin conformation favorable for interac- 
tion with ligands [22-27]. Activation of different VLA 
integrins can be achieved with mAb specific for the fll 
subunit [24-27]. These mAb induce interaction of VLA- 
2, VLA-4, VLA-5 and VLA-6 with ECM proteins 
COLL, FN and LM as well as interaction of VLA-4 with 
the cellular ligand VCAM-1 [11-13,24-27]. 
Whereas, as mentioned above, the regulation of func- 
tion of VLA-2, VLA-3, VLA-4, VLA-5 and VLA-6 has 
been characterized, very few studies on the control of 
functional activity of VLA-1 have been reported so far, 
probably due to the limited availability of anti-VLA-1 
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mAbs that block the interaction of this integrin with 
ligands. In this report, we describe the regulation of the 
functional activity of VLA-1 expressed on a neuroblas- 
toma cell line by divalent cations and stimulatory anti-ill 
mAb TS2/16 by using a novel blocking VLA-~I specific 
mAb. 
2. Materials and methods 
2.1. Cells and cell cultures 
The neuroblastoma cell line NB100 and the melanoma cell line DX3 
were obtained from the Imperial Cancer Research Fund (London, 
UK). These two cell lines were grown in RPMI medium supplemented 
with 10% FCS (Biowhittaker, Fontenay Sous Bois, France), 50 IU/ml 
penicillin, 50/ag/ml streptomycin (ICN Biomedicals, Costa Mesa, CA). 
2.2. Antibodies 
The following mAb were obtained in our laboratory and described 
elsewhere: HC1/1 (CD1 lc) [28], D3/9 (CD45) [29], Lia 3/2 (CD18) [30], 
Lia 1/2 (CD29) [9], HP2/I (CD49d) [9]. mAb Tea 1/41 (CD49b) was 
obtained in our laboratory and will be described elsewhere. The mAb 
TS2/7 (CD49a) [31], TS2/16 (CD29) [31], 12F1 (CD49b) [32], P1B5 
(CD49c) [33], GoH3 (CD49f) [34] have been previously described. 
2.3. Affinity chromatography purification of ill integrins 
For purification of totalill integrins an immunoaffinity chromatog- 
raphy column was prepared by covalently coupling purified anti-ill 
mAb TS2/16 (at 2 mg/ml) to 3 mi of CNBr-activated CL-4B Sepharose 
(Pharmacia Fine Chemicals, Uppsala, Sweden) following the manufac- 
turer's instructions. 
A mixture of ill integrins was obtained from Triton X-100 lysates of 
normal human spleen. Spleen (50 g) was diced, sieved and lysed in 300 
ml of lysis buffer (20 mM Tris-HC1, 150 mM NaC1, 2 mM MgCi2, 200 
/aM MnCI2, 1% Triton X-100, 0.02% NAN3, 1 mM PMSF, 0.2 units/ml 
aprotinin and 5 mM iodoacetamide, pH 8.0) for 2 h at 40C. The cell 
lysate was centrifuged at 3,000 x g for 30 rain at 4"C and then ultracen- 
trifuged at 100,000 x g for 1 h at 4°C. The lysate was precleared by 
passing through a 2 ml pre-column of glycine-Sepharose CL-4B (pre- 
equilibrated in lysis buffer) and then loaded onto the 3 ml column of 
TS2/I 6-Sepharose CL-4B (pre-equilibrated in lysis buffer) at a flow rate 
of 0.5 ml per min. The column was then washed sequentially with 15 
ml of lysis buffer and 15 ml of washing buffer (50 mM ethanolamine, 
0.2% Triton X-100, 0.5 M NaC1, 2 mM MgC12, 200/aM MnCI2, 1 mM 
PMSF, pH 10.0) and boundill integrins were finally eluted with 50 mM 
ethanolamine, 0.5 M NaC1, 2 mM MgC12, 200/aM MnC12, 1% octylglu- 
coside, 1 mM PMSF, pH 12.0 at a flow rate of 0.5 ml per min. Fractions 
of 0.5 mi were collected and neutralized with 0.1 volume of 1 mM Tris, 
pH 6.7. Fractions containing ill integrins were identified by SDS-8% 
PAGE followed by silver staining. The yield of total ill integrins was 
estimated to be approximately 2 mg (in 10 ml of neutralized elution 
buffer) by comparison of silver staining with known amounts of BSA. 
2.4. Obtainment of mAb 5E8D9 
Balb/c mice were injected intraperitoneally with approximately 5/ag 
of affinity chromatography purified ill integrins on days -48 and -33, 
and intravenously on day -3. Spleen cells were fused on day 0 with SP2 
mouse myeloma cells at a ratio of4:1 according to standard techniques 
and distributed in 96-well plates (Costar, Cambridge, MA). After two 
weeks, hybridoma culture supernatants were harvested and screened 
for reactivity with purified ill integrins in an ELISA method and pos- 
itive hybridomas were subsequently ested for their ability to inhibit he 
adhesion of the neuroblastoma cell line NB100 to type I collagen and 
laminin. Hybridomas producing monoclonal ntibodies with inhibitory 
effect on cell adhesion were cloned by limiting dilution. Monoclonal 
antibody 5E8D9 was selected. This mAb is of the IgG2a subclass. 
2.5. lmmunoprecipitation 
NB 100 neuroblastoma and DX3 melanoma cells were iodinated with 
0.5 mCi sodium [t25I]iodide (ICN Biomedicals, Irvine, Ca) using 1,3,4,6- 
tetrachloro-3ct,6ct-diphenylglycoluril (Iodogen, Sigma, St. Louis, MI) 
and lysed in phosphate buffered saline (PBS), 1% Triton X-100, 1% 
haemoglobin, 1 mM PMSF, pH 7.4 for 15 min. For immunoprecipita- 
tion, equal amounts of radioactive cell lysates were incubated at 4°C 
with 100/al of corresponding hybridoma culture supernatants. After 
2 h, 100/al of culture supernatant containing the rat anti-mouse-IgG 
mAb 187.1 were added and incubation proceeded for an additional 
period of 2 h at 4°C. Finally, immunoprecipitates were removed by 
addition of 30/al of protein A~Sepharose, incubation for 1 h with 
continuous tirring and centrifugation at200 x g followed by process- 
ing as previously described [28]. Samples were analyzed on SDS-8% 
polyacrylamide gels followed by autoradiography with enhancing 
screens .  
2.6. Flow cytometric analysis 
Flow cytometry was performed as previously described [19,35]. 
Briefly, 105 cells were incubated for 30 min on ice with 50/al of culture 
supernatant or a 1:100 dilution of ascites fluid from the corresponding 
mAb in each well of a flexiwell plate (Dynatech), washed 3 times with 
200/al of RPMI and incubated for an additional period of 30 min with 
50/al of a 1 : 100 dilution of FITC-conjugated sheep anti-mouse IgG 
secondary antibody (Sigma). After appropriate washes with PBS, cells 
were fixed in 200/al of 5% formaldehyde in PBS and their fluorescence 
determined with a FACScan flow cytometer (Becton Dickinson). 
2. Z Cell attachment assays 
Laminin was a generous gift from Dr. M.A. Lizarbe (Departamento 
de Bioquimica y Biologia Molecular, Facultad de Ciencias Quimicas, 
Universidad Complutense, Madrid). Collagen type I (Vitrogen 100) 
was purchased from ICN Biomedicals. The adhesion assays were essen- 
tially performed as previously described [26]. Briefly, 96-well flat-bot- 
tomed plates (Titertek, ICN Biomedicals) were coated overnight at 4 ° C 
with either laminin or collagen at 20/ag/ml in PBS. After one wash with 
200/al of PBS, wells were saturated for 1 h at room temperature with 
boiled 1% BSA in PBS. Plates were then washed three times with PBS 
and once with 200/al of HEPES buffer (20 mM HEPES, 150 mM NaCI, 
2 mg/ml D-glucose, pH 7.4) and 50/al of HEPES buffer containing the 
appropriate dilutions of purified mAb and the chlorides of divalent 
cations Mga+/EGTA, Ca ~+, and Mn 2+ or EDTA were added to the wells. 
Cells (105) in 50/al of HEPES buffer were added to each well and plates 
were incubated for 45 min at 37°C. The percentage of cells that re- 
mained adhered after three washes of wells with 200/al of HEPES buffer 
was calculated measuring the absorbance of wells at 540 nm after 
fixation of adhered cells with 3% formaldehyde in PBS for 10 min and 
then for 10 min with 2% methanol followed by staining with 0.5% 
Crystal violet in 20% methanol, washing with water and elution of stain 
with 0.1 M sodium citrate pH 4.2 in 50% ethanol. 
3. Results 
The initial selection of hybridomas producing mAb 
specific for VLA integrins was made based on their reac- 
tivity with human purified total ill integrins immobilized 
on plastic by an ELISA method (data not shown). For 
functional selection of mAb specific for VLA integrins, 
the ELISA-positive hybridoma culture supernatants 
were subsequently analyzed for their ability to inhibit the 
adhesion of neuroblastoma (NB100) and melanoma 
(DX3) cells to the ECM proteins type I collagen and 
laminin. As shown in Fig. 1, adhesion of NB100 and 
DX3 cells to these two proteins in medium containing 
2 mM Mg 2* and 2 mM Ca 2+ was mediated by ill inte- 
grins since it was completely inhibited by preincubation 
of the cells with the mAb Lia 1/2 which binds to a func- 
tionally relevant epitope on the common ill subunit 
[9,26]. 
We selected the mAb 5E8D9 for its ability to block the 
adhesion of neuroblastoma NB100 cells to type I colla- 
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Fig. 1. Adhesion of human euroblastoma NB100 cells to collagen type 
I is blocked by anti-VLA-1 mAb 5E8D9. The adhesion of NB100 cells 
to collagen type I but not to laminin was inhibited by mAb 5E8D9. The 
adhesion of human melanoma DX3 cells to either collagen or laminin 
was not affected by mAb 5E8D9. The mAb Lia 1/2 specific for the 
commonfll subunit ofVLA integrins completely blocked the adhesion 
of both cell lines to either collagen type I or laminin. Cell attachment 
assay was performed in HEPES buffer containing 2 mM Mg 2+, 2 mM 
Ca 2+ and 10 pg/ml of corresponding mAb as described in section 2. 
Data are representative of five independent experiments. 
the common 130 kDaf l l  subunit from both NB100 and 
DX3 cell lines (Fig. 2). Immunoprecipitation with the 
control anti-VLA-1 mAb TS2/7 showed that the two 
bands corresponding to the ~1 (CD49a) and fll (CD29) 
subunits have exactly the same molecular weight as those 
obtained with mAb 5E8D9, thus indicating that this 
mAb is specifically recognizing the a subunit of VLA-1. 
Also, the pattern of surface staining with the control 
anti-VLA-1 mAb TS2/7 was identical to that observed 
with mAb 5E8D9 for all the different ypes of haemopoi- 
etic and non-haemopoietic cells tested, which confirms 
the specificity of this mAb for the al  integrin. In con- 
trast, control mAb specific for CD49b, CD49c, CD49d, 
CD49e and CD49f showed patterns of staining on the 
different cell types analyzed clearly different to those 
obtained with mAb 5E8D9 or TS2/7 (data not shown). 
As we had found that adhesion of neuroblastoma 
NB100 cells to type I collagen in medium containing 
Ca 2÷ and Mg 2÷ was mainly mediated by integrin VLA-1 
we characterized in more detail this adhesion system and 
used it for the study of the regulation by divalent cations 
of the functional activity of integrin VLA-1. We first 
analyzed the expression on NB100 and DX3 cells of the 
VLA heterodimers known to mediate the adhesion of 
other cell types to collagen or laminin (Fig. 3). VLA-1 
(COLL/LM), VLA-2 (COLL/LM) and VLA-3 (FN/ 
1 2 3 4 5 6 7 8 9 10 11 
m 200 kd 
165 kd 
130 kd 
gen (Fig. 1). Interestingly, the adhesion of this cell line 
to laminin was not affected by mAb 5E8D9. In contrast, 
the adhesion of the melanoma cell line DX3 to either 
laminin or type I collagen was unaffected by mAb 
5E8D9, suggesting that under the same conditions these 
two cell types may utilize other different VLA hetero- 
dimers for efficient adherence to type I collagen and 
laminin. 
The nature of the molecule recognized by mAb 5E8D9 
was determined by immunoprecipitation a alysis from 
lysates of 125I-surface labeled NB100 and DX3 ceils and 
comparison with other VLA heterodimers precipitated 
with different anti-VLA 0c andfl mAbs. The mAb 5E8D9 
immunoprecipitated a 200 kDa subunit associated with 
NB 100 DX3 
Fig. 2. Immunoprecipitation withmAb 5E8D9 from 12SIdabeled lysates 
of melanoma DX3 and neuroblastoma NB100 cells, mAb 5E8D9 im- 
munoprecipitates twobands of 200 and 130 kDa (lanes 5and 11) which 
correspond tothe VLA-1 heterodimer as determined bycomparison 
with the control anti-VLA-cO (CD49a) mAb TS2/7 (lanes 3 and 9). 
Other control mAb used were: HC1/1 (CD1 lc) lanes 4 and 10, TS2/16 
(CD29) lanes 1 and 7, Tea 1/41 (CD49b) lanes 2 and 8 and HP2/1 
(CD49d) lane 6. Immune complexes were isolated, and reduced samples 
were subjected toSDS-8% PAGE and autoradiography as described in
section 2. 
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Fig. 3. Cell surface xpression of VLA collagen and laminin receptors 
on neuroblastoma NB100 and melanoma DX3 ceils. The level of sur- 
face expression of CD18 (negative control), VLA-1 (CD49a), VLA-2 
(CD49b), VLA-3 (CD49c), VLA-6 (CD49f) and fll (CD29) integrin 
subunits was determined by flow cytometry as described in section 2. 
MAb used were: Lia 3/2 (CD18), TS2/7 (CD49a), Tea 1/41 (CD49b), 
P1B5 (CD49c), GoH3 (CD49f). 
COLL/LM) ct subunits were differentially expressed in 
NB100 and DX3 cell lines whereas the level of VLA-6 
(LM) expression was very similar in both cell lines. Spe- 
cifically, the level of VLA-1 expression in NB100 cells 
was dearly higher than in DX3, which would account for 
the lack of inhibitory effect of mAb 5E8D9 on the adhe- 
sion of DX3 to collagen previously observed. Also, com- 
parison of the levels of surface expression among the 
three VLA integrins known to mediate cell adhesion to 
collagen showed that on NB 100 cells VLA-1 is expressed 
at a remarkably higher level than VLA-2 or VLA-3, 
which again could explain the blocking effect of mAb 
5E8D9 on the adhesion of this cell line to type I collagen. 
We next studied the regulation of functional activity 
of VLA-1 by divalent cations Ca 2÷, Mg 2÷ and Mn2÷by 
using the interaction of NB100 cells with type I collagen. 
For both Mg 2÷ and Mn 2÷ the percentage of NB100 cells 
that adhered to type I collagen increased with the con- 
centration of divalent cation present in the medium (Fig. 
4A). At relatively low concentrations of cations, cell ad- 
hesion was mainly mediated by VLA-1, as indicated by 
the potent inhibitory effect hat preincubation with mAb 
5E8D9 had under all conditions. The level of inhibition 
of cell adhesion with this mAb was lower at higher con- 
centrations of divalent cations, which may reflect the 
cation-induced activation of other collagen binding VLA 
integrins (VLA-2 or VLA-3) on these cells. For all the 
divalent cation concentrations u ed, adhesion of NB100 
cells to type I collagen was completely dependent on the 
activity of VLA integrins, as demonstrated by blockade 
with the anti-ill mAb Li0d/2. As reported for other inte- 
grins [19], the minimal concentration of divalent cation 
required for effective VLA-l-mediated adhesion was 50- 
fold higher for Mg 2+ than for Mn 2÷ suggesting that the 
later binds to one or several of the three divalent cation 
binding sites on the CD49a with much higher affinity. On 
the contrary, Ca 2÷ even at concentrations ofup to 5 mM 
was not able to support he interaction of VLA-1 with 
type I collagen (not shown). Despite the fact that Ca 2÷ 
alone did not induce the activation of VLA-1, the ques- 
tion of whether this divalent cation could act as a poten- 
tiator of the Mg2+-supported interaction of integrin 
VLA-1 with ligand still remained open. As shown in Fig. 
4B, Ca 2+ did not exert any potentiating effect on the 
adhesion induced by Mg 2÷ (at 2 mM) but clearly had a 
concentration dependent inhibitory effect. As expected, 
no VLA-l-mediated adhesion of NB100 cells to type I 
collagen was observed in the absence of divalent cations. 
Finally, we investigated whether the integrin VLA-1 
on NB100 cells can be directly activated by the anti-ill 
mAb TS2/16 resulting in increased adhesion to ligand 
type I collagen as previously described for VLA-3, VLA- 
4, VLA-5 and VLA-6 in a number of different cell sys- 
tems [11-12,26,36]. Fig. 5A shows that mAb TS2/16 ef- 
fectively augmented the percentage of NB100 cells that 
adhere to collagen under all the different cation condi- 
tions tested. However, this TS2/16-induced increment in 
cell adhesion to type I collagen due to activation of VLA 
integrins could only be marginally inhibited with mAb 
5E8D9, indicating that other collagen receptors, namely 
VLA-2 and VLA-3, although expressed at lower levels 
than VLA-1 on NB100 cells, become also directly acti- 
vated by mAb TS2/16. Interestingly, in the presence of 
mAb TS2/16, adhesion of NB100 cells to type I collagen 
was supported by concentrations of Ca 2÷ in the mM 
range. However, this Ca2+-supported a hesion was min- 
imally inhibited by mAb 5E8D9, again suggesting that 
under these conditions of activation of ill integrins with 
mAb TS2/16 cell adherence to type I collagen is mediated 
not only by VLA-1 but also by VLA-2 or/and VLA-3. 
To determine whether VLA-1 on NB100 cells actually 
becomes directly activated by mAb TS2/16, we assessed 
whether the inhibitory effect of mAb 5E8D9 on cell ad- 
hesion was more evident in the situation where cell adhe- 
sion to collagen is induced in Ca 2÷ with mAb TS2/16 and 
partially inhibited with an anti-VLA-2 mAb. Under 
these conditions, the anti-VLA-1 mAb 5E8D9 had a 
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Fig. 4. Divalent cation dependency ofthe VLA-l-mediated adhesion of human euroblastoma NB 100 cells to collagen type I. (A) Mg 2÷ (in the presence 
of 1 mM EGTA) at concentrations in the mM range and Mn 2÷ at concentrations in the mM range induce VLA-l-mediated cell adhesion to collagen 
in a dose dependent manner. (B) Ca 2÷ inhibits the VLA-l-mediated cell adhesion induced by 2 mM Mg 2÷ in a dose-dependent manner, mAb 5E8D9 
was used at a final concentration f 10 pg/ml. Cell attachment assays were performed as described in section 2. Data are representative of five different 
experiments. 
clear additive inhibitory effect on cell adhesion indicat- 
ing that mAb TS2/16 activates not only VLA-2 but also 
VLA-1 on NB-100 cells (Fig. 5B). 
4. Discussion 
In this paper we describe the regulation of the func- 
tional activity of the integrin VLA-1 (CD29a) by divalent 
cations Mg 2÷, Ca 2÷ and Mn 2÷ and also by the stimulatory 
anti-ill mAb TS2/16. 
We have used the adhesion of the neuroblastoma 
NB100 cell line to type I collagen as a model system for 
the study of functional activation of VLA- 1. These neu- 
roblastoma cells express on their surface high levels of 
VLA- 1 but only moderate l vels of VLA-2 and low levels 
of VLA-3 and, therefore, constitute an excelent model 
for analysis of VLA-1 function. This study has been 
facilitated by the generation of a novel CD49a specific 
mAb that effectively blocks the interaction of the VLA- 1 
heterodimer with type I collagen. This anti-VLA-1 mAb 
was obtained by immunizing mice with a mixture of total 
ill integrins purified from human ormal spleen. The use 
of an immunoaffinity column with the stimulating anti- 
ill mAb TS2/16 covalently linked to sepharose and the 
presence of Mn 2÷ and Mg 2÷ throughout the integrin puri- 
fication and immunization protocols were aimed at pre- 
serving ill integrins in an active conformation able to 
interact with appropriate ligands. For functional selec- 
tion of mAbs specific for ill integrins we assessed their 
ability to inhibit the adherence of neuroblastoma 
(NB100) and melanoma (DX3) cell lines to the ECM 
proteins type I collagen and laminin which are ligands 
for VLA-1, VLA-2, VLA-3 and VLA-6 integrins. The 
mAb 5E8D9 was selected for its ability to block the 
adhesion of NB 100 cells to type I collagen. On the con- 
trary, this mAb had no effect on the adhesion of DX3 
cells to the same ECM protein. These results indicated 
that mAb 5E8D9 might be specifically recognizing the a 
subunit of VLA-1 as neuroblastoma NB100 cells do ex- 
press a remarkably higher molecular density of VLA-1 
on their surface than melanoma DX3 cells and, there- 
fore, the adherence ofthese two cell lines to collagen was 
expected to be differentially affected by an anti-VLA-1 
mAb. The specificity of mAb 5E8D9 for VLA-1 was 
confirmed by immunoprecipitation a d comparative 
analysis of the cell surface xpression of this molecule 
with the control anti-VLA-1 rnAb TS2/7. 
Under physiological divalent cation conditions, i.e. in 
the presence of extracellular concentrations of Mg 2÷ and 
Ca 2÷ in the range of 1-2 mM, a significant percentage 
(35-40%) of NB100 cells adhere to type I collagen and 
this adhesion is mediated by VLA integrins as demon- 
strated by complete blocking with the CD29 mAb 
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Fig. 5. Stimulatory anti-ill mAb TS2/16 activates VLA-1 on NB100 cells. (A) mAb TS2/16 induces an important increase in cell adhesion to collagen 
type I under all divalent cation conditions. No enhancement of cell adhesion to collagen type I in the absence of divalent cation (EDTA) or to bovine 
serum albumin (BSA) in the presence of Ca 2÷ and Mg 2÷ was induced by mAb TS2/16. (B) TS2/16-induced increment in cell adhesion to collagen type 
I is inhibited by anti-VLA-1 (5E8D9) and anti-VLA-2 (12F1) mAb. Divalent cation concentrations u ed were: [Mn2+], 50/zM; [Ca2÷+Mg2÷], 1 mM 
Ca 2÷ and 2 mM Mg2*; [Mg2÷+EGTA], 2 mM Mg~÷/1 mM EGTA; [Ca2+], 2 mM; [EDTA], 2 mM. All mAb were used at a final concentration of
10 gg/ml. Data are representative of five different experiments. 
Liofl/2. Using mAb 5E8D9 we have demonstrated that 
under these cation conditions adhesion of NB100 cells to 
type I collagen is basically mediated by the integrin 
VLA-1. The fact that combination of Mg2÷/Ca 2+ sup- 
ports VLA-l-mediated cell adhesion i dicates that under 
physio-logical conditions VLA-1 is constitutively active 
and capable of mediating interaction with ligands. This 
constitutive partial activation of VLA-1 expressed on 
neuroblastoma NB100 cells clearly contrasts with mem- 
bers of other families of integrins uch as the leukocyte 
integrin LFA-1, where the presence of low concentra- 
tions of Ca 2÷ completely inactivate this integrin render- 
ing leukocytes unable to interact with ligand ICAM-1 
[18]. This difference in the cation-controlled basal activa- 
tion state of different integrins may be related to the cell 
type and has important physiological relevance, as rest- 
ing leukocytes are normally non-adherent circulating 
cells that do not interact with other cells or ECM pro- 
teins unless they become activated, whereas neuroblas- 
toma or melanoma cells have generally a constitutive 
adherent phenotype. 
Our data also demonstrate that the activity of VLA-1 
expressed on human euroblastoma NB100 cells is con- 
trolled by divalent cations Ca 2+, Mg 2+ or Mn 2÷ in a dose- 
dependent manner. Both Mg 2+ and Mn 2÷ induce the acti- 
vation of VLA-1 possibly by imposing a conformation 
which favours interaction with ligand upon binding to 
one or more of the three cation binding sites present on 
the ~ subunit. Conversely, Ca 2÷ does not support he 
interaction of VLA-1 with collagen but exerts strong 
negative ffects on the Mg2+-induced activation of this 
adhesion receptor. These regulatory mechanisms exerted 
by divalent cations on the activity of VLA-1 are similar 
to those described for other fll integrins (VLA3, VLA-4, 
and VLA-6) as well as integrins belonging to the f12 and 
f13 families in a number of cell and soluble systems [11- 
15,17,19-21]. Therefore, general regulatory mechanisms 
by which divalent cations control the functional activity 
of integrins are now emerging that span different integrin 
families. 
We have also shown that function of the VLA-1 heter- 
odimer can be regulated through the fll chain by the 
specific TS2/16 anti-ill mAb. Under all the cation condi- 
tions tested, mAb TS2/16 increased the percentage ofcell 
adhesion to collagen, reflecting the activation of VLA 
integrins. However, in the total absence of divalent cati- 
ons no enhancement i  cell adhesion was observed with 
mAb TS2/16, confirming the absolute requirement for 
divalent cations of VLA integrins to mediate ffective 
adhesion to ligands. Interestingly, in the presence of 
mAb TS2/16, mM concentrations of Ca 2+ are able to 
support an important percentage of VLA-1 (and VLA- 
2)-mediated cell adhesion to collagen. This finding of 
reversion by mAb TS2/16 of the Ca2+-induced inhibition 
284 A. Luque et al. / FEBS Letters 346 (1994) 278-284 
of adhesion has been also recently described for VLA-3 
[10] and indicates that the conformational change in- 
duced by mAb TS2/16 in different VLA integrins is not 
sufficient o mediate ffective cell adhesion to ligands 
unless binding of cation to specific sites on the a subunit 
occurs. The fact that NB100 ceils express, in addition to 
VLA- 1, other collagen receptors on their surface, namely 
VLA-2 and VLA-3, may explain that the inhibition of 
cell adhesion observed with mAb 5E8D9 was never com- 
plete. 
The physiological relevance of cation usage by inte- 
grins can be envisioned assuming that extracellular Ca 2+ 
maintains the integrins on resting cells in a state of low 
or basal activation until specific stimuli nduce activation 
of cells altering the conformation of the integrins which 
in turn results in increased cell adhesion to appropriate 
ligands. Accordingly, stimulatory mAb such as TS2/16, 
which induces activation of fll integrins, or NKI-L16 
which induces activation of the f12 integrin LFA-I, are 
thought to activate integrins by inducing similar confor- 
mational changes to those brought about as a conse- 
quence of cell activation. 
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